Drug Profile
Mirvetuximab soravtansine companion diagnostic - ImmunoGen/Roche Tissue Diagnostics
Alternative Names: VENTANA FOLR1 (FOLR1-2.1) RxDx AssayLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen; Ventana Medical Systems
- Developer ImmunoGen; Roche Tissue Diagnostics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ovarian cancer